Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials
This article, published in Pediatrics, evaluated the overall safety profile of the 9-valent human papillomavirus (9vHPV) vaccine across seven Phase 3 studies in 9 to 26 year old males and females (nonpregnant at entry). The authors found that the 9vHPV vaccine was generally well tolerated among research subjects with a safety profile similar to that of the quadrivalent HPV vaccine. The findings support widespread 9vHPV vaccination. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Moreira ED, Block SL, Ferris D, et al.
» Visit web page (English)
(Located at pediatrics.aappublications.org)
Citation: Moreira ED, Block SL, Ferris D, et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016;138(2):e20154387.
Resource types: Peer-reviewed journal
Diseases/vaccines: Human papillomavirus (HPV)
Regions: North America and Europe